Expertise:
Peritoneal Mesothelioma
HIPEC
Gastric Cancer
Pancreatic Cancer
Colorectal Cancer
Speciality:
Surgical Oncology
Gender:
Male
Language:
English, Hebrew

Get to Know Dr. Joshua H. Winer

Innovative surgical oncologist Dr. Joshua Winer treats patients with peritoneal mesothelioma, specializing in the novel hyperthermic intraperitoneal chemotherapy procedure, or HIPEC, that has improved outcomes dramatically in recent years.

In 2013, Winer joined Winship Cancer Institute at Emory University, where he started the HIPEC program, which delivers heated, highly concentrated chemotherapy directly into the abdomen to kill any tumor cells that remain after cytoreductive surgery.

In addition to mesothelioma, Winer also treats gastric, colorectal, pancreatic and hepatobiliary cancers. His research interests are focused on improving treatment for patients through the latest intraoperative technology applications.

Winer serves as an assistant professor of surgery within the division of surgical oncology at the Emory University School of Medicine in Atlanta.

Winship Cancer Institute is a renowned medical facility and the only one in Georgia with the prestigious National Cancer Institute designation. Its specialists and research teams have come together to produce some of the country’s leading multidisciplinary treatment programs.

Specialties of Dr. Joshua H. Winer

  • Cytoreductive surgery
  • HIPEC
  • Peritoneal mesothelioma cancer
  • Pancreatic cancer
  • Neuroendocrine tumors
  • Liver cancer
  • Appendix cancer

Dr. Joshua H. Winer’s Experience and Medical Education

  • Winship Cancer Institute
  • Emory University School of Medicine
  • University of Pittsburgh Medical Center (Fellowship)
  • Brigham and Women’s Hospital (Residency)
  • University of Maryland Medical Center (M.D.)

Awards and Certifications

  • American Board of Surgery
  • American College of Surgeons
  • Society of Surgical Oncology
  • Georgia state medical license

Publications of Dr. Joshua H. Winer

  • Violette, C. et al. (2021, January 26). Fertility after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A call to action. Journal of Surgical Oncology.
  • Turgeon, M.K. et al. (2020, May 6). The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. Annals of Surgical Oncology.
  • Gamboa, A.C. et al. (2019, October 16). Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel? Journal of Surgical Oncology.